Refine
Has Fulltext
- yes (152)
Is part of the Bibliography
- yes (152)
Year of publication
Document Type
- Journal article (152) (remove)
Language
- English (152) (remove)
Keywords
- children (11)
- inflammation (9)
- preterm infants (8)
- bronchopulmonary dysplasia (5)
- infection (5)
- influenza (5)
- IL-10 (4)
- Medizin (4)
- Ureaplasma parvum (4)
- autoimmunity (4)
- disease (4)
- immunotherapy (4)
- juvenile idiopathic arthritis (4)
- macrophages (4)
- monocytes (4)
- pediatric (4)
- treatment (4)
- vaccination (4)
- CRMO (3)
- HBMEC (3)
- NK cells (3)
- T cells (3)
- Th17 (3)
- Ureaplasma urealyticum (3)
- burden (3)
- cells (3)
- cytokines (3)
- immunization (3)
- physical activity (3)
- preterm birth (3)
- sepsis (3)
- surfactants (3)
- therapy (3)
- B cell (2)
- B cells (2)
- CNO (2)
- COVID-19 (2)
- Children (2)
- Cystic fibrosis (2)
- DIRA (2)
- Exercise capacity (2)
- Exercise testing (2)
- Germany (2)
- PAPA (2)
- Physical activity (2)
- Pädiatrie (2)
- Rheumatologie (2)
- SARS-CoV-2 (2)
- T cell receptor excision circles (2)
- TLR4 (2)
- TNF-α (2)
- Tregs (2)
- Wilms' tumor (2)
- animal model (2)
- blood–brain barrier (2)
- bone (2)
- cancer (2)
- case report (2)
- chronic non-bacterial osteomyelitis (2)
- chronic nonbacterial osteomyelitis (2)
- chronic recurrent multifocal osteomyelitis (2)
- cord blood (2)
- cystic fibrosis (2)
- deficiency (2)
- efficacy (2)
- endothelial cells (2)
- epithelial cells (2)
- expression (2)
- flow cytometry (2)
- gene (2)
- glucocorticoids (2)
- hospitalizations (2)
- hypophosphatasia (2)
- hypoxia (2)
- immunoblotting (2)
- in vitro (2)
- innate immunity (2)
- leukemia (2)
- medicine (2)
- meningitis (2)
- messenger RNA (2)
- neonate (2)
- neonates (2)
- nervous system (2)
- neuroinflammation (2)
- pediatric adrenocortical cancer (2)
- pediatric adrenocortical tumor (2)
- pediatrics (2)
- preterm (2)
- preterm infant (2)
- regulatory T cells (2)
- sustained inflammation (2)
- transplantation (2)
- treatment guidelines (2)
- tumor (2)
- tumor microenvironment (2)
- ACP5 (1)
- AD-AID (1)
- AICDA (1)
- AID-ΔE4a (1)
- ALPL (1)
- ARDS (1)
- Abatacept (1)
- Accelerometry (1)
- Age (1)
- Allogeneic stem cell transplantation (1)
- Anti-TNF-alpha agents (1)
- Antibody (1)
- Apoptosis (1)
- Aspergillus (1)
- Aspergillus fumigatus (1)
- Autoinflammation (1)
- B cell deficiency (1)
- B cell maturation (1)
- B cell receptor (1)
- B-cell (1)
- B4GALT7 gene (1)
- BPD (1)
- Bevacizumab (1)
- Big picture (1)
- Blood stream infection (1)
- Body composition (1)
- Bone health (1)
- Bronchopulmonary dysplasia (1)
- C-reactive protein (1)
- C5a (1)
- C5aR1 (1)
- CAR-T cells (1)
- CCN2 (1)
- CD105 (1)
- CD3/19 depletion (1)
- CD34 selection (1)
- CD62L (1)
- CD8 (1)
- CDR3 sequences (1)
- CMV (1)
- CNS cancer (1)
- CNS integrity (1)
- CTGF (1)
- CVID (1)
- CXCL5 (1)
- CXCL8 (1)
- CXCR2 (1)
- Cardiovascular disease (1)
- Caspase (1)
- Central venous access (1)
- Childhood cancer survivors (1)
- Chimeric Antigen Receptor T cells (1)
- Chorioamnionitis (1)
- Cigarette smoking (1)
- Coverage (1)
- Cushing (1)
- Cytokine GM-CSF (1)
- DC vaccination (1)
- DNA methylation (1)
- DNA-binding proteins (1)
- DWI (1)
- Deutschland (1)
- Disease severity (1)
- Diseases (1)
- Dixon (1)
- E. coli (1)
- ECORN-CF Projekt (1)
- ESPED (1)
- EU-RHAB registry (1)
- England (1)
- Epidemiology (1)
- Epidural Analgesia (1)
- Escherichia coli (1)
- European experience (1)
- Exacerbation (1)
- Exercise intervention (1)
- Extraocular eye muscles (1)
- FADS (1)
- Foxp3 (1)
- GLDN variant (1)
- Gamma (1)
- Gastroenteritis (1)
- Glut1DS (1)
- Graft-versus-host disease (1)
- Grippe (1)
- H441 (1)
- HLA-G gene (1)
- HPP (1)
- HRQOL (1)
- Healthcare Cost (1)
- Healthcare Economics (1)
- Hemagglutination inhibition (1)
- Hickman catheter (1)
- Hospitalisation (1)
- Hospitalization (1)
- ICD-10 (1)
- IL-1 beta (1)
- IL-1 blockade (1)
- IL-10 expression (1)
- IL-12B (1)
- IL-12p40 (1)
- IL-17A-inhibition (1)
- IL12B (1)
- IMR-90 (1)
- IgD (1)
- IgG (1)
- IgM (1)
- Immunogenicity (1)
- Immunosenescence (1)
- Immunotherapy (1)
- Incidence (1)
- Incontinentia pigmenti (1)
- Infectious disease (1)
- Influenza (1)
- Influenza vaccination (1)
- JIA (1)
- Jugend (1)
- Juvenile idiopathic arthritis (1)
- Keuchhusten (1)
- Kindergarten (1)
- LCCS11 (1)
- LND (1)
- LNE (1)
- Labour Analgesia (1)
- Labour Pain (1)
- Late-effects (1)
- Longitudinal analysis (1)
- Lung disease, (1)
- Lymphocytes (1)
- M1/M2 macrophages (1)
- MDSC (1)
- MHC I (1)
- MHC II (1)
- MRI spectroscopy (1)
- MTL30 (1)
- Majeed (1)
- Majeed-Syndrome (1)
- Mechanisms (1)
- Medicine (1)
- Meningitis (1)
- Metastases (1)
- Minor histocompatibility antigen mismatch transplantation (1)
- Mucopolysaccharidosis IIIa (1)
- Muscle function (1)
- Muscle power (1)
- NADPH oxidase (1)
- NBAS (1)
- NK cell deficiency (1)
- Naive T cells (1)
- Necrotizing enterocolitis (1)
- Neuroinflammation (1)
- OPT (1)
- Oxygen uptake (1)
- P67(PHOX) (1)
- PAPA syndrome (1)
- PET/CT (1)
- PLAG1 rearrangement (1)
- POEM (1)
- PU.1 (1)
- Paediatric (1)
- Patient Controlled Analgesia (1)
- Patient Satisfaction (1)
- Pediatric (1)
- Pediatric malignancy (1)
- Phosphorylation (1)
- Physical fitness (1)
- Pneumococcal vaccination (1)
- Port (1)
- Preterm birth (1)
- Prevalence (1)
- Quality of life (1)
- Questionnaire (1)
- RNA isolation (1)
- RSV-A ON1 (1)
- RTPS1 (1)
- RTPS2 (1)
- Randomized controlled trial (1)
- Regulatory T cells (1)
- Regulatory T-cells (1)
- Remifentanil (1)
- Respiratory tract infection (1)
- Retinopathy (1)
- Rhabdomyosarcoma (1)
- Risk (1)
- Rituximab (1)
- Rotavirus (1)
- SB332235 (1)
- SIRP-alpha (1)
- SMAD signaling (1)
- Safety (1)
- Schnitzler syndrome (1)
- Staphylococcus aureus (1)
- Surveillance (1)
- T and NK development (1)
- T cell plasticity (1)
- T lymphocytes (1)
- T-cell (1)
- T-cell responses (1)
- TB (1)
- TCR diversity (1)
- TH1-induced senescence (1)
- TH17 cells (1)
- TLR agonists (1)
- TMJ (1)
- TNAP (1)
- TREC (1)
- TRECs (1)
- T\(_H\)17 cells (1)
- Telomere (1)
- Telomeres (1)
- Th9 (1)
- Thrombosis (1)
- Tocilizumab (1)
- Toll-like receptor signaling (1)
- Treg (1)
- Trousseau's syndrome (1)
- United States (1)
- Universal mass vaccination (1)
- Ureaplasma (1)
- Ureaplasma species (1)
- VEGF (1)
- VIBE (1)
- VLBW (1)
- Vaccination (1)
- Vaccine (1)
- Varicella (1)
- Varizellen-Virus (1)
- Viruses (1)
- Vorschulkind (1)
- Wechsler intelligence scale (WISC-IV) (1)
- Wilm's tumor (1)
- achalasia (1)
- activity (1)
- acute (1)
- acute ITP (1)
- acute graft-versus-host disease (1)
- adenocarcinoma of the lung (1)
- adolescents (1)
- adrenal cancer (1)
- adrenal surgery (1)
- adrenalectomia (1)
- adrenocortical adenocarcinoma (1)
- adrenocortical carcinoma (1)
- adults (1)
- adverse pulmonary outcomes (1)
- aging (1)
- airway remodeling (1)
- alkaline phosphatase (1)
- allogeneic stem cell transplantation (1)
- alloreactive T cells (1)
- alveolar epithelium in vitro model, claudin-1, claudin-3, claudin-4, claudin-5 (1)
- amniotic infection (1)
- anaplastic medulloblastoma (1)
- antenatal inflammation (1)
- anti inflammation (1)
- anti-tumor agents (1)
- antibacterial activity (1)
- antibiotic resistance (1)
- antibiotic therapy (1)
- antibiotic use (1)
- antibody (1)
- antidepressants (1)
- antimicrobial activity (1)
- antimicrobial immunity (1)
- antimicrobial resistance (1)
- antimicrobial stewardship (1)
- antinuclear antibodies (1)
- anuria (1)
- anxiety disorders (1)
- apoptosis (1)
- arterial hypotension (1)
- arthrogryposis (1)
- asfotase alfa (1)
- asymmetry (1)
- atypical chemokine receptor 3 (1)
- atypical teratoid rhabdoid tumors (1)
- autoimmune encephalitis (1)
- autoinflammation (1)
- autologous stem cell transplantation (1)
- autophagy (1)
- axonopathy (1)
- barrier (1)
- beta-D-glucan (1)
- biomarker (1)
- bioreactor culture (1)
- bisphosphonate treatment (1)
- blastocysts (1)
- bleding disorders other than hemophilia (1)
- bleeding score (1)
- bone autoinflammation (1)
- bovine lactoferricin (1)
- brain development (1)
- brain tumor (1)
- breast cancer (1)
- breastfeeding (1)
- breath-hold (1)
- bronchopulmonary dysplasia (BPD) (1)
- bullae (1)
- caffein (1)
- caffeine (1)
- cancer microenvironment (1)
- cancer stem cells (1)
- cancer vaccines (1)
- cancer-targeted IL-12 (1)
- cardiogenic (1)
- cardiovascular risk (1)
- cell therapy (1)
- cellular signalling networks (1)
- central venous catheter (1)
- cerebral calcification (1)
- childhood leukemia (1)
- chorioamnionitis (1)
- chronic pulmonary insufficiency of prematurity (1)
- cidofovir (1)
- clinical application (1)
- clinical trial (1)
- cloning (1)
- coagulopathy (1)
- cognitive profile (1)
- combinatorial drug predictions (1)
- combined therapy (1)
- common variable immunodeficiency (1)
- complication (1)
- computer modelling (1)
- condyle pathomorphology (1)
- congenital dyserythropoietic anemia (1)
- connective tissue disorder (1)
- continuous positive airway pressure (CPAP) (1)
- corticosteroids (1)
- coverage (1)
- craniosynostosis (1)
- cytokine (1)
- cytoskeleton (1)
- cytotoxic effect (1)
- dendritic cells (1)
- depression (1)
- derivatives (1)
- desmoplastic small round cell tumor (1)
- diagnosis (1)
- diagnostic delay (1)
- diaphragmatic hypomotility (1)
- differentiation (1)
- diffusion-weighted MRI (1)
- disease severity (1)
- double negative B cells (1)
- drug therapy (1)
- dry lung syndrome (1)
- dual guidance (1)
- dysplasia (1)
- early onset sepsis (1)
- effector cells (1)
- endogenous pulmonary stem cells (1)
- endoglin (1)
- epidemiology (1)
- epitope mapping (1)
- essential tremor (1)
- exercise intervention (1)
- exercise testing (1)
- exercise tolerance (1)
- exposure (1)
- extracellular vesicles (1)
- extracorporeal membrane oxygenation (1)
- extracranial malignant rhabdoid tumor (1)
- factor XIII deficiency (1)
- familial hemophagocytic lymphohistiocytosis (1)
- fetal lung (1)
- fibrosis (1)
- follow up (1)
- forearm (1)
- fungal infection (1)
- gadoxetic acid (1)
- galactomannan (1)
- galectin-1 (1)
- galectin-3 (1)
- galectin-9 (1)
- gender gap (1)
- gene expression (1)
- general practitioner (1)
- genetics (1)
- genome-wide association study (1)
- genotype-phenotype correlation (1)
- germline mutation (1)
- glioblastoma multiforme (1)
- gliomedin (1)
- graft-versus host (1)
- group 3 (1)
- health (1)
- healthcare costs (1)
- healthy children (1)
- hematology (1)
- hemorrhagic (1)
- hemostasis and thrombosis (1)
- henoch-schönlein purpura (1)
- hospital exemption (1)
- hospitalization (1)
- human brain endothelium (1)
- human brain microvascular endothelial cells (1)
- human cerebral endothelial cells (1)
- human monocytes (1)
- humanized mice (1)
- humans (1)
- hyper-IgM syndrome type 2 (HIGM2) (1)
- hyperfibrinolysis (1)
- hyperoxia (1)
- hypertrophic osteodystrophy (1)
- hypogammaglobulinemia (1)
- imaging (1)
- immaturity (1)
- immune reconstitution (1)
- immune response (1)
- immunocytokine (1)
- immunodeficiency (1)
- immunoglobulin repertoire (1)
- immunoglobulins (1)
- immunology (1)
- immunomodulation (1)
- immunosenescence (1)
- immunotherapies (1)
- inattention/hyperactivity (1)
- inborn error of immunity (1)
- infection spread (1)
- infections: pneumonia (1)
- infectious diseases management (1)
- inflammatory diseases (1)
- influenza A virus (1)
- influenza vaccination (1)
- inhibit (1)
- innate immune response (1)
- innate immunity training (1)
- intelligence (1)
- intensive care (1)
- interferon gamma (1)
- interleukin-8 (1)
- interleukin-9 (1)
- interventional radiology (1)
- intravenous immunoglobulins (1)
- invasiveness (1)
- ischemia/reperfusion injury (1)
- juvenile progressive respiratory insufficiency (1)
- ketogenic dietary therapy (KDT) (1)
- knowledge (1)
- lactoferricin B (1)
- late onset sepsis (1)
- lethality rate (1)
- lines (1)
- lipoblastoma (1)
- liquid biopsy (1)
- live-attenuated influenza vaccine (1)
- long-term outcome (1)
- loop region (1)
- luciferase (1)
- lung (1)
- lung injury (1)
- lung transplantation (1)
- lymph node dissection (1)
- lymphadenectomy (1)
- lymphocytes (1)
- lymphoplasmacellular osteomyelitis (1)
- maintenance therapy (1)
- malignant glioma (1)
- maternal critical care (1)
- measles (1)
- mechanisms (1)
- mesenchymal stromal cell (1)
- meta-analysis (1)
- metabolic reprogramming (1)
- metabolic syndrome (1)
- metabolism (1)
- metanalysis (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- methylation (1)
- mhc molecules (1)
- mice (1)
- microbiome (1)
- middle cerebral artery occlusion (1)
- mineralization (1)
- mitophagy (1)
- modular tumor tissue models (1)
- monocyte subsets (1)
- monocyte-derived DC (1)
- mouse models (1)
- movement disorder (1)
- movement disorders (1)
- multiple myeloma (1)
- multiple sclerosis (1)
- multiresistance (1)
- multi‑center cohort study (1)
- murine model (1)
- mutation (1)
- mutational targeting (1)
- myeloid (1)
- naive T cells (1)
- near infrared spectroscopy (1)
- neoepitope-derived peptides (1)
- neonatal immunology (1)
- neonatal meningitis (1)
- neonatal morbidity (1)
- neonatal outcome (1)
- neonatal renal failure (1)
- neuroblastoma (1)
- neuroblastoma – diagnosis (1)
- neurocognitive outcome (1)
- neutrophils (1)
- newly diagnosed ITP (1)
- non-invasive respiratory support (1)
- non-invasive ventilation (1)
- non-responder (1)
- nutrition education (1)
- observational (1)
- obstetrics (1)
- oligohydramnios sequence (1)
- orthotopic xenograft (1)
- osteomalacia (1)
- outcome (1)
- outpatient (1)
- p.R245H (1)
- p.S298P (1)
- paediatric cancer (1)
- pancreatic carcinoma (1)
- panic disorder (1)
- partially-supervised (1)
- participation in clinical trials (1)
- pediatric adrenocortical adenoma (1)
- pediatric adrenocortical carcinoma (1)
- pediatric immune thrombocytopenia (1)
- pediatric patients (1)
- pediatric stem cell transplantation (1)
- pediatrician (1)
- perioperative bleeding (1)
- peroral endoscopic myotomy (1)
- persistence (1)
- phosphorylation (1)
- platelet disorders (1)
- polymicrobial infection (1)
- polymorphism (1)
- population coverage (1)
- post-pandemic (1)
- potter sequence (1)
- prediction (1)
- pregnancy (1)
- prematurity (1)
- preschool children (1)
- preterm children (1)
- prevention program (1)
- primary antibody deficiency (1)
- primary care (1)
- primary immunodeficiencies (1)
- primary schoolchildren (1)
- probiotic prophylaxis (1)
- prognostic factors (1)
- prognostic marker (1)
- promoter (1)
- prophylaxis (1)
- prostaglandin E2 (1)
- protein expression (1)
- quality of life (1)
- quality-control (1)
- radiotherapy (1)
- randomised controlled trial (1)
- rare bone disease (1)
- rare diseases (1)
- rat (1)
- re-aim framework (1)
- real-time PCR (1)
- recommendations (1)
- refractory aGvHD (1)
- region (1)
- regional cerebral oxygenation saturation (1)
- regulatory dendritic cells (1)
- renal tubular dysgenesis (1)
- reoxygenation (1)
- resident memory T cells (1)
- resistant acid phosphatase (1)
- resolution (1)
- respiratory distress (1)
- respiratory distress syndrome (RDS) (1)
- respiratory-distress-syndrome (1)
- retroperitoneal tumor (1)
- review (1)
- rhabdomyosarcoma (1)
- rheumatoid arthritis (1)
- rickets (1)
- risk factors (1)
- safety (1)
- scoliosis (1)
- seasonal influenza (1)
- septic (1)
- serum (1)
- shock (1)
- shuttle run test (1)
- skin-to-skin contact (1)
- soft tissue sarcoma (1)
- soluble endoglin (1)
- somatic hypermutation (1)
- spectrum (1)
- speech motor impairment (1)
- spondylodysplastic Ehlers-Danlos syndrome (1)
- spondyloenchondrodysplasia (1)
- standard (1)
- stem/progenitor cells (1)
- steroid-resistant aGvHD (1)
- strength and difficulties (1)
- streptococci (1)
- stroke (1)
- suppression (1)
- suppressive function (1)
- surfactant (1)
- surfactant protein-A (1)
- surveillance (1)
- survey (1)
- sustained lung inflation (SLI) (1)
- sweat osmolality (1)
- sweat secretion rate (1)
- synovial fluid (1)
- synovitis (1)
- synthetic peptides (1)
- synthetic surfactant (1)
- systemic lupus erythematosus (1)
- systemic sclerosis (1)
- teeth (1)
- telomere length (1)
- telomeres (1)
- therapeutic vaccines (1)
- therapy response (1)
- thermoregulation (1)
- thymectomy (1)
- thymus (1)
- tight junctions (1)
- tool (1)
- totally implantable venous access port (1)
- trained immunity (1)
- transcription factors (1)
- transmission (1)
- transmission model (1)
- trap (1)
- tremor (1)
- tumor-infiltrating lymphocytes (1)
- tumor-specific CD8+ T cells (1)
- tumors (1)
- tumour immunology (1)
- type I interferonopathy (1)
- vaccine (1)
- varicella (1)
- varicella-zoster virus immunosuppression (1)
- vascular access (1)
- vascular disturbances (1)
- vascular homeostasis (1)
- vasculitis (1)
- vasopressin (1)
- vesicle trafficking (1)
- viral (1)
- volume (1)
- young children (1)
- zebrafish (1)
Institute
- Kinderklinik und Poliklinik (152) (remove)
Sonstige beteiligte Institutionen
- Department of Medicinal Chemistry, University of Vienna, Althanstraße 14, 1090 Vienna, Austria (1)
- Department of Paediatric Radiology, Institute of Diagnostic and Interventional Radiology, Josef-Schneider-Straße 2, Wuerzburg 97080, Germany (1)
- Department of Pediatrics, Pediatrics I, Innsbruck Medical University, Anichstr. 35, 6020, Innsbruck, Austria (1)
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Althanstraße 14, 1090 Vienna, Austria (1)
- Interdisciplinary Center for Clinical Research (IZKF), Würzburg, Germany (1)
- Interdisziplinäres Zentrum für Klinische Forschung (IZKF) (1)
EU-Project number / Contract (GA) number
- 229289 (1)
- 241778 (1)
- 609,020 (1)
- HEALTH-F2-2009-241778 (1)
Background
The epidural route is still considered the gold standard for labour analgesia, although it is not without serious consequences when incorrect placement goes unrecognized, e.g. in case of intravascular, intrathecal and subdural placements. Until now there has not been a viable alternative to epidural analgesia especially in view of the neonatal outcome and the need for respiratory support when long-acting opioids are used via the parenteral route. Pethidine and meptazinol are far from ideal having been described as providing rather sedation than analgesia, affecting the cardiotocograph (CTG), causing fetal acidosis and having active metabolites with prolonged half-lives especially in the neonate. Despite these obvious shortcomings, intramuscular and intravenously administered pethidine and comparable substances are still frequently used in delivery units.
Since the end of the 90ths remifentanil administered in a patient-controlled mode (PCA) had been reported as a useful alternative for labour analgesia in those women who either don’t want, can’t have or don’t need epidural analgesia.
Discussion
In view of the need for conversion to central neuraxial blocks and the analgesic effect remifentanil has been demonstrated to be superior to pethidine. Despite being less effective in terms of the resulting pain scores, clinical studies suggest that the satisfaction with analgesia may be comparable to that obtained with epidural analgesia. Owing to this fact, remifentanil has gained a place in modern labour analgesia in many institutions.
However, the fact that remifentanil may cause harm should not be forgotten when the use of this potent mu-agonist is considered for the use in labouring women. In the setting of one-to-one midwifery care, appropriate monitoring and providing that enough experience exists with this potent opioid and the treatment of potential complications, remifentanil PCA is a useful option in addition to epidural analgesia and other central neuraxial blocks. Already described serious consequences should remind us not refer to remifentanil PCA as a “poor man’s epidural” and to safely administer remifentanil with an appropriate indication.
Summary
Therefore, the authors conclude that economic considerations and potential cost-savings in conjunction with remifentanil PCA may not be appropriate main endpoints when studying this valuable method for labour analgesia.
Background
The aim of the study was to evaluate the effects of universal mass vaccination (UMV) against rotavirus (RV) on the hospitalization rates, nosocomial RV infections and RV-gastroenteritis (GE)-associated secondary blood stream infections (BSI).
Methods
The retrospective evaluation (2002–2009) by chart analysis included all clinically diagnosed and microbiologically confirmed RV-GE cases in a large tertiary care hospital in Austria. The pre-vaccination period (2002–2005) was compared with the recommended and early funded (2006–2007) and the funded (2008–2009) vaccination periods. Primary outcomes were RV-GE-associated hospitalizations, secondary outcomes nosocomial RV disease, secondary BSI and direct hospitalization costs for children and their accompanying persons.
Results
In 1,532 children with RV-GE, a significant reduction by 73.9% of hospitalized RV-GE cases per year could be observed between the pre-vaccination and the funded vaccination period, which was most pronounced in the age groups 0–11 months (by 87.8%), 6–10 years (by 84.2%) and 11–18 years (88.9%). In the funded vaccination period, a reduction by 71.9% of nosocomial RV-GE cases per year was found compared to the pre-vaccination period. Fatalities due to nosocomial RV-GE were only observed in the pre-vaccination period (3 cases). Direct costs of hospitalized, community-acquired RV-GE cases per year were reduced by 72.7% in the funded vaccination period. The reduction of direct costs for patients (by 86.9%) and accompanying persons (86.2%) was most pronounced in the age group 0–11 months.
Conclusions
UMV may have contributed to the significant decrease of RV-GE-associated hospitalizations, to a reduction in nosocomial RV infections and RV-associated morbidity due to secondary BSI and reduced direct hospitalization costs. The reduction in nosocomial cases is an important aspect considering severe disease courses in hospitalized patients with co-morbidities and death due to nosocomial RV-GE.
The blood-air barrier in the lung consists of the alveolar epithelium, the underlying capillary endothelium, their basement membranes and the interstitial space between the cell layers. Little is known about the interactions between the alveolar and the blood compartment. The aim of the present study was to gain first insights into the possible interplay between these two neighboured cell layers. We established an in vitro Transwell model of the alveolar epithelium based on human cell line H441 and investigated the influence of conditioned medium obtained from human lung endothelial cell line HPMEC-ST1.6R on the barrier properties of the H441 layers. As control for tissue specificity H441 layers were exposed to conditioned medium from human brain endothelial cell line hCMEC/D3. Addition of dexamethasone was necessary to obtain stable H441 cell layers. Moreover, dexamethasone increased expression of cell type I markers (caveolin-1, RAGE) and cell type II marker SP-B, whereas decreased the transepithelial electrical resistance (TEER) in a concentration dependent manner. Soluble factors obtained from the lung endothelial cell line increased the barrier significantly proven by TEER values and fluorescein permeability on the functional level and by the differential expression of tight junctional proteins on the molecular level. In contrast to this, soluble factors derived from brain endothelial cells weakened the barrier significantly. In conclusion, soluble factors from lung endothelial cells can strengthen the alveolar epithelium barrier in vitro, which suggests communication between endothelial and epithelial cells regulating the integrity of the blood-air barrier.
Synergistic Effect of Caffeine and Glucocorticoids on Expression of Surfactant Protein B (SP-B) mRNA
(2012)
Administration of glucocorticoids and caffeine is a common therapeutic intervention in the neonatal period, but possible interactions between these substances are still unclear. The present study investigated the effect of caffeine and different glucocorticoids on expression of surfactant protein (SP)-B, crucial for the physiological function of pulmonary surfactant. We measured expression levels of SP-B, various SP-B transcription factors including erythroblastic leukemia viral oncogene homolog 4 (ErbB4) and thyroid transcription factor-1 (TTF-1), as well as the glucocorticoid receptor (GR) after administering different doses of glucocorticoids, caffeine, cAMP, or the phosphodiesterase-4 inhibitor rolipram in the human airway epithelial cell line NCI-H441. Administration of dexamethasone (1 mM) or caffeine (5 mM) stimulated SP-B mRNA expression with a maximal of 38.8611.1-fold and 5.261.4-fold increase, respectively. Synergistic induction was achieved after coadministration of dexamethasone (1 mM) in combination with caffeine (10 mM) (206659.7-fold increase, p,0.0001) or cAMP (1 mM) (2136111-fold increase, p = 0.0108). SP-B mRNA was synergistically induced also by administration of caffeine with hydrocortisone (87.9639.0), prednisolone (154666.8), and betamethasone (12366.4). Rolipram also induced SP-B mRNA (64.9621.0-fold increase). We detected a higher expression of ErbB4 and GR mRNA (7.0- and 1.7-fold increase, respectively), whereas TTF-1, Jun B, c-Jun, SP1, SP3, and HNF-3a mRNA expression was predominantly unchanged. In accordance with mRNA data, mature SP-B was induced significantly by dexamethasone with caffeine (13.869.0-fold increase, p = 0.0134). We found a synergistic upregulation of SP-B mRNA expression induced by co-administration of various glucocorticoids and caffeine, achieved by accumulation of intracellular cAMP. This effect was mediated by a caffeinedependent phosphodiesterase inhibition and by upregulation of both ErbB4 and the GR. These results suggested that caffeine is able to induce the expression of SP-transcription factors and affects the signaling pathways of glucocorticoids, amplifying their effects. Co-administration of caffeine and corticosteroids may therefore be of benefit in surfactant homeostasis.
Connective tissue growth factor (CTGF/CCN2) is an angiogenetic and profibrotic factor, acting downstream of TGF-b, involved in both airway- and vascular remodeling. While the T-helper 1 (Th1) cytokine interferon-gamma (IFN-c) is well characterized as immune-modulatory and anti-fibrotic cytokine, the role of IFN-c in lung endothelial cells (LEC) is less defined. Tumour necrosis factor alpha (TNF-a) is another mediator that drives vascular remodeling in inflammation by influencing CTGF expression. In the present study we investigated the influence of IFN-c and TNF-a on CTGF expression in human LEC (HPMEC-ST1.6R) and the effect of CTGF knock down on human LEC. IFN-c and TNF-a down-regulated CTGF in human LEC at the promoter-, transcriptional- and translational-level in a dose- and time-dependent manner. The inhibitory effect of IFN-c on CTGF-expression could be almost completely compensated by the Jak inhibitor AG-490, showing the involvement of the Jak-Stat signaling pathway. Besides the inhibitory effect of IFN-c and TNF-a alone on CTGF expression and LEC proliferation, these cytokines had an additive inhibitory effect on proliferation as well as on CTGF expression when administered together. To study the functional role of CTGF in LEC, endogenous CTGF expression was down-regulated by a lentiviral system. CTGF silencing in LEC by transduction of CTGF shRNA reduced cell proliferation, but did not influence the anti-proliferative effect of IFN-c and TNF-a. In conclusion, our data demonstrated that CTGF was negatively regulated by IFN-c in LEC in a Jak/Stat signaling pathway-dependent manner. In addition, an additive effect of IFN-c and TNF-a on inhibition of CTGF expression and cell proliferation could be found. The inverse correlation between IFN-c and CTGF expression in LEC could mean that screwing the Th2 response to a Th1 response with an additional IFN-c production might be beneficial to avoid airway remodeling in asthma.
Background: The 2009 pandemic influenza A (H1N1) (PIA) virus infected large parts of the pediatric population with a wide clinical spectrum and an initially unknown complication rate. The aims of our study were to define clinical characteristics and outcome of pandemic influenza A (H1N1) 2009-associated hospitalizations (PIAH) in children <18 years of age. All hospitalized cases of children <18 years of age with laboratory-confirmed pandemic influenza A (H1N1) 2009 in the region of Wuerzburg (Northern Bavaria, Germany) between July 2009 and March 2010 were identified. For these children a medical chart review was performed to determine their clinical characteristics and complications. Results: Between July 2009 and March 2010, 94 PIAH (62% males) occurred in children <18 years of age, with a median age of 7 years (IQR: 3–12 years). Underlying diseases and predisposing factors were documented in 40 (43%) children; obesity (n = 12, 30%), asthma (n = 10, 25%) and neurologic disorders (n = 8, 20%) were most frequently reported. Sixteen (17%) children received oxygen supplementation; three (3%) children required mechanical ventilation. Six (6%) children were admitted to an intensive care unit, four of them with underlying chronic diseases. Conclusions: Most PIAH demonstrated a benign course of disease. However, six children (6%) needed treatment at an intensive care unit for severe complications.
Background: The objective of this study was to validate physical activity questionnaires for cystic fibrosis (CF) against accelerometry and cycle ergometry. Methods: 41 patients with CF (12-42 years) completed the Habitual Activity Estimation Scale (HAES), the 7-Day Physical Activity Recall questionnaire (7D-PAR) and the Lipid Research Clinics questionnaire (LRC) and performed an incremental exercise test according to the Godfrey protocol up to volitional fatigue. Time spent in moderate and vigorous physical activity (MVPA) assessed objectively by accelerometry was related to the time spent in the respective activity categories by correlation analyses and calculating intraclass correlation coefficients (ICC). Furthermore, the results of the exercise test were correlated with the results of the questionnaires. Results: Time spent in the categories ‘hard’,’very hard’ and ‘hard & very hard’ of the 7D-PAR (0.41 < r < 0.56) and ‘active’ (r = 0.33) of the HAES correlated significantly with MVPA. The activity levels of the LRC were not related to objectively determined physical activity. Significant ICCs were only observed between the 7D-PAR activitiy categories and MVPA (ICC = 0.40-0.44). Only the LRC showed moderate correlations with the exercise test (Wmax: r = 0.46, p = 0.002; VO2peak: r = 0.32, p = 0.041). Conclusions: In conclusion, the activity categories ‘hard’ and ‘very hard’ of the 7D-PAR best reflected objectively measured MVPA. Since the association was at most moderate, the 7D-PAR may be selected to describe physical activity within a population. None of the evaluated questionnaires was able to generate valid physical activity data exercise performance data at the individual level. Neither did any of the questionnaires provide a valid assessment of aerobic fitness on an invidual level.
Background: The European Centres of Reference Network for Cystic Fibrosis (ECORN-CF) established an Internet forum which provides the opportunity for CF patients and other interested people to ask experts questions about CF in their mother language. The objectives of this study were to: 1) develop a detailed quality assessment tool to analyze quality of expert answers, 2) evaluate the intra- and inter-rater agreement of this tool, and 3) explore changes in the quality of expert answers over the time frame of the project. Methods: The quality assessment tool was developed by an expert panel. Five experts within the ECORN-CF project used the quality assessment tool to analyze the quality of 108 expert answers published on ECORN-CF from six language zones. 25 expert answers were scored at two time points, one year apart. Quality of answers was also assessed at an early and later period of the project. Individual rater scores and group mean scores were analyzed for each expert answer. Results: A scoring system and training manual were developed analyzing two quality categories of answers: content and formal quality. For content quality, the grades based on group mean scores for all raters showed substantial agreement between two time points, however this was not the case for the grades based on individual rater scores. For formal quality the grades based on group mean scores showed only slight agreement between two time points and there was also poor agreement between time points for the individual grades. The inter-rater agreement for content quality was fair (mean kappa value 0.232 ± 0.036, p < 0.001) while only slight agreement was observed for the grades of the formal quality (mean kappa value 0.105 ± 0.024, p < 0.001). The quality of expert answers was rated high (four language zones) or satisfactory (two language zones) and did not change over time. Conclusions: The quality assessment tool described in this study was feasible and reliable when content quality was assessed by a group of raters. Within ECORN-CF, the tool will help ensure that CF patients all over Europe have equal possibility of access to high quality expert advice on their illness.
Background: Data on complications in children with seasonal influenza virus infection are limited. We initiated a nation-wide three-year surveillance of children who were admitted to a paediatric intensive care unit (PICU) with severe seasonal influenza. Methods: From October 2005 to July 2008, active surveillance was performed using an established reporting system for rare diseases (ESPED) including all paediatric hospitals in Germany. Cases to be reported were hospitalized children < 17 years of age with laboratory-confirmed influenza treated in a PICU or dying in hospital. Results: Twenty severe influenza-associated cases were reported from 14 PICUs during three pre-pandemic influenza seasons (2005-2008). The median age of the patients (12 males/8 females) was 7.5 years (range 0.1-15 years). None had received vaccination against influenza. In 14 (70%) patients, the infection had been caused by influenza A and in five (25%) by influenza B; in one child (5%) the influenza type was not reported. Patients spent a median of 19 (IQR 12-38) days in the hospital and a median of 11 days (IQR 6-18 days) in the PICU; 10 (50%) needed mechanical ventilation. Most frequent diagnoses were influenza-associated pneumonia (60%), bronchitis / bronchiolitis (30%), encephalitis / encephalopathy (25%), secondary bacterial pneumonia (25%), and ARDS (25%). Eleven (55%) children had chronic underlying medical conditions, including 8 (40%) with chronic pulmonary diseases. Two influenza A- associated deaths were reported: i) an 8-year old boy with pneumococcal encephalopathy following influenza infection died from cerebral edema, ii) a 14-year-old boy with asthma bronchiale, cardiac malformation and Addison’s disease died from cardiac and respiratory failure. For nine (45%) patients, possibly permanent sequelae were reported (3 neurological, 3 pulmonary, 3 other sequelae). Conclusions: Influenza-associated pneumonia and secondary bacterial infections are relevant complications of seasonal influenza in Germany. The incidence of severe influenza cases in PICUs was relatively low. This may be either due to the weak to moderate seasonal influenza activity during the years 2005 to 2008 or due to underdiagnosis of influenza by physicians. Fifty % of the observed severe cases might have been prevented by following the recommendations for vaccination of risk groups in Germany.
Acellular Pertussis Booster in Adolescents Induces Th1 and Memory CD8+ T Cell Immune Response
(2011)
In a number of countries, whole cell pertussis vaccines (wcP) were replaced by acellular vaccines (aP) due to an improved reactogenicity profile. Pertussis immunization leads to specific antibody production with the help of CD4+ T cells. In earlier studies in infants and young children, wcP vaccines selectively induced a Th1 dominated immune response, whereas aP vaccines led to a Th2 biased response. To obtain data on Th1 or Th2 dominance of the immune response in adolescents receiving an aP booster immunization after a wcP or aP primary immunization, we analyzed the concentration of Th1 (IL-2, TNF-a, INF-c) and Th2 (IL-4, IL-5, IL-10) cytokines in supernatants of lymphocyte cultures specifically stimulated with pertussis antigens. We also investigated the presence of cytotoxic T cell responses against the facultative intracellular bacterium Bordetella pertussis by quantifying pertussis-specific CD8+ T cell activation following the aP booster immunization. Here we show that the adolescent aP booster vaccination predominantly leads to a Th1 immune response based on IFNgamma secretion upon stimulation with pertussis antigen, irrespective of a prior whole cell or acellular primary vaccination. The vaccination also induces an increase in peripheral CD8+CD69+ activated pertussis-specific memory T cells four weeks after vaccination. The Th1 bias of this immune response could play a role for the decreased local reactogenicity of this adolescent aP booster immunization when compared to the preceding childhood acellular pertussis booster. Pertussis-specific CD8+ memory T cells may contribute to protection against clinical pertussis.